L eber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) disorder in the United Kingdom, with a minimum prevalence of 1 in 31,000.
1,2 Three mtDNA point mutations account for ~ 90% of all LHON cases and m.11778G>A is the most frequently identified (~70%) pathogenic variant worldwide (Table 1) . 3, 4 It is an important cause of severe visual loss among young adults with a peak age of onset in the second and third decades of life. Management is mostly supportive but recent developments in LHON research are pointing the way towards more effective treatments for this blinding mitochondrial disorder.
Clinical features of LHON
LHON classically presents with acute or subacute painless loss of central vision. The initial visual loss is severe with most patients achieving best corrected visual acuities of 6/60 or worse. 3, 4 There is an associated dense central scotoma and a marked reduction in colour perception. Despite this global reduction in optic nerve function, the pupillary light reflexes are relatively preserved, and this distinctive feature has been ascribed to a special class of melanopsin-containing retinal ganglion cells (RGCs), which are less vulnerable to the downstream consequences of the mtDNA LHON mutations. 5 Bilateral optic nerve involvement occurs in ~25% of LHON cases. If sequential, the second eye is invariably affected within one year of disease onset, unilateral optic neuropathy being exceptionally rare in LHON. 3, 4 In the acute phase, optic disc hyperaemia, peripapillary telangiectatic vessels, vascular tortuosity, and retinal nerve fibre layer oedema can be observed, the latter being due to RGC axonal stasis ( Figure 1) . 3, 4 In the pre-molecular era, these fundal abnormalities were particularly informative, allowing a presumptive diagnosis of LHON to be made, especially when supported by a maternal family history of early-onset visual loss. In 20-40% of acute cases, the optic discs look entirely normal and these patients are often incorrectly labelled as having functional visual loss. 3, 4 Pallor of the neuroretinal rim develops within six weeks of disease onset and it is initially more apparent temporally due to the accelerated loss of RGC Leber Hereditary Optic NeuropathyTherapeutic Challenges and Early Promise * These mtDNA variants are definitely pathogenic. They have been identified in ≥ 2 independent LHON pedigrees, showing segregation with affected disease status. The remaining putative LHON mutations have been found in singleton cases or in a single family, and additional evidence is required before pathogenicity can be irrefutably ascribed. 3 4 Common variants (~ 90%)
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axons within the papillomacular bundle. Extra-ocular features such as cardiac conduction defects, peripheral neuropathy, dystonia, and myopathy are thought to be more common among LHON carriers compared with the general population. 3, 4 There is also a wellestablished association between the three primary LHON mutations and a demyelinating illness, which interestingly is clinically and radiologically indistinguishable from multiple sclerosis (Harding's disease). 6 Other rarer pathogenic mtDNA variants have been linked with more atypical 'LHON plus' syndromes where the optic neuropathy is complicated by prominent spastic dystonia, ataxia, juvenile-onset encephalopathy, and psychiatric disturbances. 3, 4 Visual prognosis The visual prognosis in LHON is poor and most patients remain legally blind. The likelihood of visual recovery is greatest with the m.14484T>C mutation, least with the m.11778G>A mutation, and intermediate with the m.3460G>A mutation. 3, 4 Although delayed visual recovery has been reported, maximal improvement in visual function usually occurs within the first year, if it occurs at all. The appearance of small islands of vision within the patient's visual field (fenestrations) can greatly help scanning vision, especially if the central scotoma becomes concurrently less dense.
Genetic counselling
The mitochondrial genome is maternally inherited and thousands of mtDNA molecules are present in metabolically-active cells. As a result of this high-copy number genome, two possible situations can arise, known as homoplasmy and heteroplasmy. Among LHON families, 85-90% of carriers are homoplasmic for the mtDNA mutation, i.e. 100% mutant, whereas the remainder are heteroplasmic harbouring a mixture of both wild-type and mutant mtDNA species. 2 The risk of disease conversion is low if the mutational load is below the threshold level of 60%. 7 Male LHON carriers can be reassured that their children will not inherit their mitochondrial genetic defect. On the other hand, female LHON carriers will transmit the mutation to all their offspring. For the minority of mothers with heteroplasmic LHON mutations, it is difficult to accurately predict the mutational level that will be transmitted since rapid generational shifts in mitochondrial allele frequencies can occur due to the 'mitochondrial bottleneck' operating in the female germline. 8 Based on published figures, some indication of recurrence risks can be provided to maternal relatives of a LHON proband (Table 2 ).
Although it is not possible to predict whether or when a LHON carrier will be affected, epidemiological studies have identified major risk factors for visual loss, namely age, sex and environmental exposure. 2 4 Over 90% of LHON carriers who will experience visual failure will do so before the age of 50 years. In addition, LHON is characterised by a marked sex bias, male carriers having a ~50% lifetime risk of developing the optic neuropathy compared with only ~10% for female carriers. Unaffected LHON carriers should be strongly advised not to smoke and to minimise their alcohol intake, not only as a general health measure, but because smoking, and to a lesser extent excessive alcohol intake, have been associated with increased risks of disease conversion. 3, 4 In one large study comparing 196 affected and 206 unaffected carriers from 125 LHON families, light and heavy smokers were twice and three times more likely to lose vision compared to non-smokers, respectively. 
Treatment strategies
Mitochondria provide the bulk of the cell's adenosine triphosphate (ATP) requirements through the tightly-regulated control of electron flux along the mitochondrial respiratory chain. All three primary LHON mutations; m.3460G>A, m.11778G>A, and m.14484T>C disrupt key polypeptide subunits of complex I, resulting in a significant bioenergetic deficit and raised levels of reactive oxygen species (ROS). 10 An intriguing aspect of the pathophysiology of LHON still remains: why are RGCs selectively vulnerable to disturbed mitochondrial function? Several hypotheses have been proposed based on the distinct anatomical, physiological, and cytoskeletal arrangements present within the optic nerve. 10 Notwithstanding these unresolved issues, the final pathological outcome in LHON is apoptotic RGC loss and the aims of treatment for this disorder are threefold: (i) to prevent initial visual loss among LHON carriers, (ii) to protect the unaffected fellow eye in patients with unilateral optic neuropathy, and (iii) to preserve visual function in already compromised optic nerves.
Neuroprotection
Various treatment 'cocktails' have been used to mitigate the deleterious impact of mitochondrial dysfunction on RGC survival. 3, 4 Coenzyme Q10 (CoQ 10) is a quinone analogue and based on limited evidence, it is frequently prescribed to patients with mitochondrial disease. Idebenone is a related compound, a shorter-chain synthetic benzoquinone analogue, which is thought to have a better bioavailability profile compared with CoQ 10. 11 Idebenone is able to bypass complex I inhibition and by shuttling electrons directly from the cytosol to complex III, ATP production is optimised with a decrease in toxic ROS levels. 11 This dual mode of action is an attractive therapeutic combination and anecdotally, some patients with LHON have experienced The recurrence risks for the m.3460G>A mutation have not been determined in a large number of pedigrees. However, these are unlikely to differ significantly from the reported estimates for the m.11778G>A and m.14484T>C LHON mutations. 3 4 Figure 1: Fundal appearance in acute and chronic LHON stages. This 47-year-old m.11778G>A male carrier experienced visual loss in his right eye first, followed by his left eye eight months later. These fundal pictures were taken one month after the left eye had become involved. Best corrected visual acuities at that point were counting fingers in the right eye and 6/36 in the left eye. There is vascular tortuosity in both eyes and temporal pallor of the right optic disc (chronic stage) due to the earlier and more pronounced loss of RGC axons within the papillomacular bundle, which sub-serves the central 10° of the visual field. There is mild hyperaemia of the left optic disc, in keeping with the recent onset of visual symptoms in that eye (acute stage).
(L = left eye; R = right eye; T = temporal quadrant corresponding to the papillomacular bundle)
significant visual recovery following treatment with idebenone. 3, 4 In collaboration with clinical partners in the UK, Germany and Canada, we therefore conducted a multicentre doubleblind randomised controlled trial (RCT) to investigate the safety, tolerability, and efficacy of high-dose idebenone in LHON. RHODOS (Rescue of Hereditary Optic Disease Outpatient Study) successfully enrolled 85 patients harbouring the three most common mtDNA LHON mutations: m.3460G>A (n=11), m.11778G>A (n=57), and m.14484T>C (n=17). 12 These patients were randomised in a 2:1 ratio to receive either high-dose idebenone (900mg) or placebo over a 24-week treatment period. A major finding of the RHODOS trial is that patients with LHON were more likely to benefit from idebenone if they were treated relatively early in the course of the disease (Figure 2) . No adverse drug reactions were reported and idebenone is currently under review by the European Medicines Agency for regulatory approval. Besides idebenone, other neuroprotective agents are also being investigated as potential treatment options in LHON. In an open-label study of four patients with acute LHON treated within 90 days of disease conversion, the antioxidant α-tocotrienol-quinone (EPI-743), a vitamin E derivative, has shown early promise and a RCT is underway to study this compound further (http://www.aosonline.org/annualmeeting/am _program.pdf, Accessed 8th of August 2011). Although their usefulness has yet to be established clinically, a marked amelioration in mitochondrial oxidative function was observed in cellular LHON models following supplementation with oestrogen-based compounds.
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Gene therapy
Gene therapy for primary mtDNA disorders is challenging. The mitochondrial inner membrane is relatively impermeable and a highly-efficient vector is needed to transfect a sufficient number of mitochondria per cell in order to rescue the disease phenotype. To circumvent these technical difficulties, a possible solution is the so-called allotopic approach where the gene of interest is transfected into the nuclear genome, and the encoded protein is engineered with a specific targeting sequence that facilitates its uptake into the mitochondrial compartment. 10 RGC loss was dramatically reduced, in both in vitro and in vivo experimental LHON models, by transfecting them with an adenovirus vector containing the human SOD2 gene.
14 In these conditions of heightened oxidative stress, the over-expression of the antioxidant enzyme superoxide dismutase is thought to promote RGC survival by exerting an anti-apoptotic influence. Another attractive and more direct approach is to replace the dysfunctional subunit encoded by the mtDNA LHON mutation. Proof of this concept has recently been demonstrated in a rat model harbouring a defective ND4 gene with the m.11778A>G mutation. 15 Visual loss was reversed by transfecting RGCs with the wild-type version of the ND4 gene, the level of transgene expression being sufficient to rescue RGCs and maintain normal physiological responses.
Looking into the future RHODOS is the first RCT for a primary mitochondrial disorder and the results obtained with high-dose idebenone are encouraging. A number of novel neuroprotective agents are currently in the pipeline for other mitochondrial cytopathies and these could also prove beneficial for patients with LHON. Gene therapy is a valid complementary approach to pharmacological intervention but long-term safety data is essential before human clinical trials can be advocated. After two decades of sustained research, we are now at the start of an exciting translational phase not only for LHON, but for other mitochondrially-determined optic neuropathies, which as a group represent an important cause of chronic visual morbidity in the population. l Figure 2 : Change in best visual acuity for patients with discordant visual acuities at baseline. Catena © is the formulation of idebenone provided by Santhera Pharmaceuticals (Liestal, Switzerland). Patients randomised to the treatment arm received a total dose of idebenone of 900mg per day, with 300mg taken three times a day during meals. Of the 85 patients enrolled into the RHODOS trial, 30 had discordant visual acuities at baseline, which was defined as a difference of more than 0.2 LogMAR between the two affected eyes. 12 This degree of visual disparity is rare in late-stage chronic LHON where patients usually have fairly symmetrical visual loss between the two affected eyes. Patients with discordant visual acuities at baseline were therefore at highest risk of further deterioration in the least affected eye, accounting for the greater treatment effect observed in this particular subgroup. (LogMAR = logarithm of the minimum angle of resolution)
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